Dr. Nicholas J. Vogelzang

Dr. Nicholas Vogelzang said a combination of passion and curiosity inspires him to continue his cancer research. It was that motivation that led him to a clinical trial that proves the chemotherapy drugs pemetrexed and cisplatin significantly reduce mesothelioma tumors.

Vogelzang is chair and medical director of the Developmental Therapeutics Committee and Co-Chair of the Genitourinary Committee for US Oncology Research at the Comprehensive Care Centers of Nevada. He is also a medical oncologist at the center.

Vogelzang is also a founding member of the Mesothelioma Applied Research Foundation (MARF) and was the board chair in 2006. He said he is optimistic about the future of disease treatment.

Mesothelioma Specialist in Nevada

Nevada is home to more than a dozen power-generator plants where asbestos has been used as a flame retardant and an electrical insulator. It was also used in the walls, floors and ceilings.

In 2013, geologists discovered a field of naturally occurring asbestos fibers in Southern Nevada, in Boulder City. In 2014, state officials started a $490 million road-construction project through a swath of land that is infested with asbestos rocks. The state department of transportation said the area was safe for construction crews. In the more densely populated parts of the state, including Henderson and Las Vegas, asbestos can be readily found in most buildings constructed before 1980.

If you are in Nevada and are seeking a skilled mesothelioma specialist, contact us today for more information. Our Patient Advocates can help you contact a mesothelioma specialist for access to quick treatment.

What are Vogelzang's specialties

Vogelzang is highly interested in drug research. His groundbreaking 2002 trial with pemetrexed and cisplatin was the largest Phase II trial for mesothelioma. A few of his other research projects include trials of varied types of chemotherapy medications for prostate cancer.

Vogelzang serves as the corporate consultant for several drug companies including Novartis AG, Veridex and Viamet.

What is Vogelzang's background

Vogelzang graduated from the University of Illinois at Chicago in 1974 with his medical degree and completed his education at Rush-Presbyterian-St. Luke’s Medical Center in Chicago and the University of Minnesota.

At the University of Chicago, he served as professor and the director of the university’s cancer research center. He was named the first Fred C. Buffett Professor of Medicine and the chair of the Genitourinary Oncology department.

From 2004 to 2009, he was the director, executive vice president for academic affairs and a professor at Nevada Cancer Institute. In 2009, he moved to Comprehensive Cancer Centers of Nevada.

Vogelzang serves on the boards of various professional, academic and medical committees, including the American Society of Clinical Oncology, the Kidney Cancer Association and the American Cancer Society. He has nearly 500 publications, both scientific and peer reviewed. He has given hundreds of lectures and presentation to his peers.